FR20C1045I1 - - Google Patents

Info

Publication number: FR20C1045I1
Authority: FR; France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-28

Filing date

2020-09-23

Publication date

2020-10-30

2020-09-23 Application filed filed Critical

2020-10-30 Publication of FR20C1045I1 publication Critical patent/FR20C1045I1/fr

2021-08-27 Application granted granted Critical

2021-08-27 Publication of FR20C1045I2 publication Critical patent/FR20C1045I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

FR20C1045C 2007-09-28 2020-09-23 Antidotes pour inhibiteurs du facteur xa et procedes d'utilisation associes Active FR20C1045I2 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US97634307P	2007-09-28	2007-09-28
US9057408P	2008-08-20	2008-08-20
PCT/US2008/078014 WO2009042962A2 (fr)	2007-09-28	2008-09-26	Antidotes pour les inhibiteurs du facteur xa et leur procédé d'utilisation
EP08834136.7A EP2193196B1 (fr)	2007-09-28	2008-09-26	Antidotes pour les inhibiteurs du facteur xa et leur procédé d'utilisation

Publications (2)

Publication Number	Publication Date
FR20C1045I1 true FR20C1045I1 (fr)	2020-10-30
FR20C1045I2 FR20C1045I2 (fr)	2021-08-27

Family

ID=40481812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR20C1045C Active FR20C1045I2 (fr)	2007-09-28	2020-09-23	Antidotes pour inhibiteurs du facteur xa et procedes d'utilisation associes

Country Status (27)

Country	Link
US (8)	US8153590B2 (fr)
EP (4)	EP3824902A1 (fr)
JP (6)	JP5637561B2 (fr)
KR (4)	KR20170100071A (fr)
CN (4)	CN103446579B (fr)
AU (6)	AU2008304192B9 (fr)
BR (2)	BRPI0816837B1 (fr)
CA (1)	CA2697583C (fr)
CY (2)	CY1118482T1 (fr)
DK (3)	DK3078743T3 (fr)
ES (3)	ES2849426T3 (fr)
FR (1)	FR20C1045I2 (fr)
HK (1)	HK1210443A1 (fr)
HR (2)	HRP20161255T1 (fr)
HU (4)	HUE052423T2 (fr)
IL (4)	IL203993A (fr)
LT (3)	LT3078743T (fr)
MX (1)	MX2010003095A (fr)
NL (1)	NL301063I2 (fr)
NO (2)	NO2019040I1 (fr)
NZ (1)	NZ583944A (fr)
PL (3)	PL2915564T3 (fr)
PT (3)	PT2915564T (fr)
SG (1)	SG185263A1 (fr)
SI (3)	SI3078743T1 (fr)
WO (1)	WO2009042962A2 (fr)
ZA (2)	ZA201002039B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7696352B2 (en) *	2004-06-18	2010-04-13	Millennium Pharmaceuticals, Inc.	Factor Xa inhibitors
US7763608B2 (en)	2006-05-05	2010-07-27	Millennium Pharmaceuticals, Inc.	Factor Xa inhibitors
ES2849426T3 (es)	2007-09-28	2021-08-18	Alexion Pharma Inc	Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
US8455439B2 (en)	2008-11-14	2013-06-04	Portola Pharmaceuticals, Inc.	Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
KR101792032B1 (ko)	2008-12-19	2017-11-02	백스터 인터내셔널 인코포레이티드	Ｔｆｐｉ 억제제 및 사용 방법
US8450275B2 (en)	2010-03-19	2013-05-28	Baxter International Inc.	TFPI inhibitors and methods of use
EP3604510A1 (fr) *	2009-03-30	2020-02-05	Portola Pharmaceuticals, Inc.	Antidotes pour inhibiteurs du facteur xa et procédés d'utilisation associes
CA2767858C (fr) *	2009-07-15	2019-02-12	Portola Pharmaceuticals, Inc.	Formulation de dose unique d'antidotes pour des inhibiteurs de facteur xa et procedes d'utilisation de celle-ci
GB0916576D0 (en) *	2009-09-22	2009-10-28	Malmsten Nils M	Polypeptides and uses thereof
ES2620421T3 (es) *	2009-10-30	2017-06-28	Senova Gesellschaft für Biowissenschaft und Technik mbH	Peptidasas acopladas a polímero
CN102762550B (zh) *	2009-12-17	2015-04-01	米伦纽姆医药公司	Xa因子抑制剂的盐和结晶形式
WO2011075602A1 (fr) *	2009-12-17	2011-06-23	Millennium Pharmaceuticals, Inc.	Procédés de préparation d'inhibiteurs du facteur xa et de leurs sels
TWI513466B (zh) *	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑
TW201240664A (en) *	2010-09-01	2012-10-16	Portola Pharm Inc	Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
AR082804A1 (es)	2010-09-01	2013-01-09	Portola Pharm Inc	Formas cristalinas de un inhibidor del factor xa
WO2012098089A1 (fr)	2011-01-19	2012-07-26	Bayer Pharma Aktiengesellschaft	Protéines de liaison à des inhibiteurs de facteurs de coagulation
FR2972114B1 (fr) *	2011-03-01	2013-03-15	Univ Grenoble 1	Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
CA2827787A1 (fr)	2011-03-30	2012-10-04	Boehringer Ingelheim International Gmbh	Antidotes aux anticoagulants
EP2760887A4 (fr)	2011-09-30	2015-06-10	Philadelphia Children Hospital	Compositions et procédés pour moduler l'homéostasie
PT2785700E (pt) *	2011-11-29	2016-06-02	Perosphere Inc	Agentes de reversão de anticoagulantes
EP2814955A1 (fr)	2012-02-14	2014-12-24	Portola Pharmaceuticals, Inc.	Procédé de fabrication d'antidote recombinant à inhibiteur du facteur xa
EP2814503A1 (fr) *	2012-02-16	2014-12-24	Portola Pharmaceuticals, Inc.	Modulation de perte de sang induite par inhibiteur du facteur xa au moyen d'une administration partielle et transitoire d'antidote
LT2827883T (lt)	2012-03-21	2019-08-12	Baxalta GmbH	Tfpi inhibitoriai ir jų panaudojimo būdai
JP6261093B2 (ja) *	2012-06-14	2018-01-17	ポートラファーマシューティカルズ，インコーポレイテッド	組み換え第Ｘａ因子誘導体の精製のための方法
EA028865B1 (ru)	2012-07-25	2018-01-31	Каталист Биосайенсиз, Инк.	Модифицированные полипептиды фактора х и их применение
US9200268B2 (en)	2012-12-27	2015-12-01	Portola Pharmaceuticals, Inc.	Compounds and methods for purification of serine proteases
FR3000895B1 (fr) *	2013-01-11	2017-02-24	Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa	Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
AU2013375294B2 (en) *	2013-01-24	2018-08-09	Portola Pharmaceuticals, Inc.	Inhibition of tissue factor pathway inhibitor with factor Xa derivatives
JP6437458B2 (ja)	2013-01-31	2018-12-12	ファイザー・インク	第Ｘａ因子の阻害を中和するための組成物および方法
FR3007410B1 (fr) *	2013-06-21	2016-05-27	Lab Francais Du Fractionnement	Facteur x depourvu de domaine gla
AU2014326257B2 (en) *	2013-09-24	2017-08-10	Pfizer Inc.	Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
EP3063170A4 (fr) *	2013-11-01	2017-06-28	The Children's Hospital of Philadelphia	Compositions et méthodes permettant d'augmenter la demi-vie du facteur xa
CA2949349A1 (fr) *	2014-05-26	2015-12-03	Academisch Ziekenhuis Leiden	Proteines prohemostatiques pour le traitement d'une hemorragie
EP3175245B1 (fr) *	2014-07-31	2019-05-29	Haemonetics Corporation	Détection et classification d'un anticoagulant à l'aide d'un test de coagulation
US10676731B2 (en)	2014-08-19	2020-06-09	The Children's Hospital Of Philadelphia	Compositions and methods for modulating factor IX function
CN107073082B (zh) *	2014-08-20	2021-04-30	博尔托拉制药公司	Xa因子解毒剂的冻干制剂
CN105030703B (zh) *	2015-06-23	2018-03-23	上海旭东海普药业有限公司	一种防治疗栓塞性疾病的利伐沙班片及其制备方法
US9849125B1 (en)	2015-11-03	2017-12-26	Banner Lifie Sciences LLC	Anti-overingestion dosage forms
WO2017147522A1 (fr)	2016-02-24	2017-08-31	Portola Pharmaceuticals, Inc.	Formulations lyophilisées pour antidote anti-facteur xa
US10640822B2 (en)	2016-02-29	2020-05-05	Iridia, Inc.	Systems and methods for writing, reading, and controlling data stored in a polymer
US10438662B2 (en)	2016-02-29	2019-10-08	Iridia, Inc.	Methods, compositions, and devices for information storage
RU2765308C2 (ru) *	2016-02-29	2022-01-28	Айридия, Инк.	Способы, композиции и устройства для хранения информации
US10859562B2 (en)	2016-02-29	2020-12-08	Iridia, Inc.	Methods, compositions, and devices for information storage
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3472314B1 (fr)	2016-06-17	2021-05-05	Alexion Pharmaceuticals, Inc.	Préparation de dérivés du facteur xa
WO2018115235A1 (fr)	2016-12-22	2018-06-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antidotes à des médicaments anticoagulants permettant le diagnostic et le traitement
EP3559047A1 (fr)	2016-12-23	2019-10-30	Novartis AG	Anticorps de facteur xi et méthodes d'utilisation
US10335375B2 (en)	2017-05-30	2019-07-02	Patheon Softgels, Inc.	Anti-overingestion abuse deterrent compositions
WO2019040532A1 (fr) *	2017-08-21	2019-02-28	Allele Biotechnology & Pharmaceuticals, Inc.	Compositions absorbant la lumière et procédés d'utilisation
EP3710486A1 (fr)	2017-11-15	2020-09-23	Novo Nordisk A/S	Liants de facteur x renforçant l'activation fx
EP3810187A4 (fr) *	2018-06-19	2022-08-31	Alexion Pharmaceuticals, Inc.	Antidotes des inhibiteurs du facteur xa
CN112261935A (zh) *	2018-08-14	2021-01-22	江苏恒瑞医药股份有限公司	一种可注射的药物组合物及其制备方法
US11655465B1 (en)	2019-05-02	2023-05-23	Iridia, Inc.	Enzymes and systems for synthesizing DNA
EP4010379A4 (fr) *	2019-08-08	2023-12-20	Alexion Pharmaceuticals, Inc.	Compositions et procédés de préparation du facteur xa et de ses dérivés
US11837302B1 (en)	2020-08-07	2023-12-05	Iridia, Inc.	Systems and methods for writing and reading data stored in a polymer using nano-channels
CN113484386B (zh) *	2021-05-21	2024-02-13	郑州轻工业大学	一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法
CN114681597A (zh) *	2022-03-11	2022-07-01	兆科药业（合肥）有限公司	蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116327627B (zh) *	2023-03-10	2024-06-07	四川大学	一种四面体框架核酸-光甘草定复合物及其在皮肤美白方面的用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH596313A5 (fr) *	1975-05-30	1978-03-15	Battelle Memorial Institute
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4754065A (en)	1984-12-18	1988-06-28	Cetus Corporation	Precursor to nucleic acid probe
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183661B (en)	1985-03-30	1989-06-28	Marc Ballivet	Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5837249A (en)	1985-04-19	1998-11-17	The Wistar Institute	Method for generating an immunogenic T cell response protective against a virus
US4818700A (en)	1985-10-25	1989-04-04	Phillips Petroleum Company	Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en)	1986-02-18	1989-03-14	Phillips Petroleum Company	Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en)	1986-09-02	1987-11-03	Ladner Robert C	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (fr)	1987-02-17	1998-04-01	Pharming B.V.	Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement
US6270961B1 (en)	1987-04-01	2001-08-07	Hyseq, Inc.	Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en)	1987-04-01	1993-04-13	Drmanac Radoje T	Method of sequencing of genomes by hybridization of oligonucleotide probes
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en)	1987-10-19	1990-05-29	Phillips Petroleum Company	Pichia transformation
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5120537A (en) *	1989-06-14	1992-06-09	Oklahoma Medical Research Foundation	Factor xa based anticoagulant compositions
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5686073A (en)	1990-05-23	1997-11-11	The University Of Iowa Research Foundation	Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
EP0542810A1 (fr)	1990-08-02	1993-05-26	B.R. Centre Limited	Procedes de production de proteines presentant une fonction souhaitee
US5278144A (en) *	1990-09-04	1994-01-11	Cor Therapeutics, Inc.	Antithrombosis agents
US5597799A (en) *	1990-09-04	1997-01-28	Cor Therapeutics, Inc.	Recombinant agents affecting thrombosis
US5583107A (en) *	1990-09-04	1996-12-10	Cor Therapeutics, Inc.	Agents affecting thrombosis and hemostasis
CA2103577A1 (fr)	1991-02-07	1992-08-08	Michael Kahn	Structures a conformation restreinte mimetiques de tours beta et de saillies beta et peptides en contenant
US6797492B2 (en)	1991-05-17	2004-09-28	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
EP0519596B1 (fr)	1991-05-17	2005-02-23	Merck & Co. Inc.	Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
RO116199B1 (ro)	1991-09-13	2000-11-30	Chiron Corp	Compozitie polipeptidica hcv imunogena
WO1993009804A1 (fr)	1991-11-18	1993-05-27	The Scripps Research Institute	Polypeptides derives de la serine protease et anticorps anti-peptidiques, systemes et procedes therapeutiques empechant la coagulation du sang
ATE297465T1 (de)	1991-11-25	2005-06-15	Enzon Inc	Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ATE249840T1 (de)	1991-12-13	2003-10-15	Xoma Corp	Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DE4203965A1 (de) *	1992-02-11	1993-08-12	Max Planck Gesellschaft	Antidot fuer hirudin und synthetische thrombininhibitoren
ATE195873T1 (de)	1992-03-20	2000-09-15	Cor Therapeutics Inc	Durch glykosylierung vermittelte hemmung des faktors x
WO1995000655A1 (fr)	1993-06-24	1995-01-05	Mc Master University	Vecteurs a base d'adenovirus destines a la therapie genique
US5858659A (en)	1995-11-29	1999-01-12	Affymetrix, Inc.	Polymorphism detection
HU223733B1 (hu)	1993-10-25	2004-12-28	Canji, Inc.	Rekombináns adenovírus vektor és eljárás alkalmazására
US5455338A (en)	1993-11-05	1995-10-03	Zymogenetics, Inc.	DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en)	1993-12-10	1999-09-14	California Institute Of Technology	Nucleic acid mediated electron transfer
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US7252989B1 (en)	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
DE4430205A1 (de)	1994-08-26	1996-02-29	Behringwerke Ag	Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5589571A (en) *	1994-10-28	1996-12-31	Cor Therapeutics, Inc.	Process for production of inhibited forms of activated blood factors
AT404357B (de)	1995-06-13	1998-11-25	Immuno Ag	Prothrombin-derivate
US5968740A (en)	1995-07-24	1999-10-19	Affymetrix, Inc.	Method of Identifying a Base in a Nucleic Acid
US5955349A (en)	1996-08-26	1999-09-21	Zymogenetics, Inc.	Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de)	1996-02-12	1997-08-14	Basf Ag	Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US6200955B1 (en)	1996-06-11	2001-03-13	Commonwealth Biotechnologies, Inc.	Heparin binding peptides
US5736383A (en)	1996-08-26	1998-04-07	Zymogenetics, Inc.	Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en)	1996-08-02	2004-03-23	Zymogenetics, Inc.	Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv) *	1996-12-20	1996-12-20	Pharmacia & Upjohn Ab	A modified coagulation agent
AT405517B (de) *	1997-02-27	1999-09-27	Immuno Ag	Faktor x-deletionsmutanten und analoge davon
AT405516B (de)	1997-02-27	1999-09-27	Immuno Ag	Faktor x-analoge mit modifizierter proteasespaltstelle
AU6673898A (en) *	1997-03-07	1998-09-22	Washington University	Factor x variant
JPH1149800A (ja) *	1997-06-05	1999-02-23	Fujimori Kogyo Kk	アンヒドロトロンビンの合成方法
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6322788B1 (en)	1998-08-20	2001-11-27	Stanley Arthur Kim	Anti-bacterial antibodies and methods of use
DK1135498T3 (da)	1998-11-18	2008-05-26	Genentech Inc	Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer
WO2000054787A1 (fr) *	1999-03-16	2000-09-21	The Children's Hospital Of Philadelphia	Gamma carboxylation amelioree de facteurs de coagulation vitamine k dependants
US6624141B1 (en)	1999-03-17	2003-09-23	The Regents Of The University Of Michigan	Protamine fragment compositions and methods of use
US6258559B1 (en)	1999-03-22	2001-07-10	Zymogenetics, Inc.	Method for producing proteins in transformed Pichia
US6939545B2 (en)	1999-04-28	2005-09-06	Genetics Institute, Llc	Composition and method for treating inflammatory disorders
US6858599B2 (en)	1999-06-30	2005-02-22	Mochida Pharmaceutical Co., Ltd.	Tricyclic compound having spiro union
AT411997B (de) *	1999-09-14	2004-08-26	Baxter Ag	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1095933A1 (fr) *	1999-10-30	2001-05-02	Aventis Pharma Deutschland GmbH	N-guanidinoalkylamides, procédé de leur préparation, leur utilisation et compositions pharmaceutiques les contenant
EP1259485B1 (fr)	2000-02-29	2005-11-30	Millennium Pharmaceuticals, Inc.	Benzamides et inhibiteurs associes du facteur xa
US6852761B2 (en) *	2000-03-13	2005-02-08	Pharmacia Corporation	Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
JP2004509617A (ja)	2000-09-08	2004-04-02	シェーリング　コーポレイション	哺乳動物遺伝子；関連試薬および方法
US7070740B1 (en)	2000-09-28	2006-07-04	Beckman Coulter, Inc.	Method and apparatus for processing biomolecule arrays
US20030064414A1 (en) *	2001-03-30	2003-04-03	Benecky Michael J.	Rapid assessment of coagulation activity in whole blood
US7138506B2 (en)	2001-05-09	2006-11-21	Genetic Id, Na, Inc.	Universal microarray system
US6989267B2 (en)	2001-07-02	2006-01-24	Agilent Technologies, Inc.	Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
DE10155075A1 (de) *	2001-11-09	2003-05-22	Merck Patent Gmbh	Cyclische Sulfonamide
US6861236B2 (en)	2002-05-24	2005-03-01	Applied Nanosystems B.V.	Export and modification of (poly)peptides in the lantibiotic way
CN1480466A (zh) *	2002-09-03	2004-03-10	�й��ž��ҽѧ��ѧԺ��ҽ	一类溶栓抗凝双功能融合蛋白及应用
US20040198660A1 (en) *	2002-11-06	2004-10-07	Petersen Lars Christian	Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en) *	2003-06-04	2007-07-24	Bristol-Myers Squibb Company	3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
EP1723422A2 (fr)	2004-03-05	2006-11-22	The Scripps Research Institute	Jeux ordonnes de microechantillons de glycanes a haut rendement
JP4441336B2 (ja)	2004-06-11	2010-03-31	日本碍子株式会社	マイクロアレイの製造方法
US9223929B2 (en)	2005-03-14	2015-12-29	The California Institute Of Technology	Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en)	2005-03-21	2006-10-10	Los Alamos National Security, Llc	Preparation of high nitrogen compound and materials therefrom
WO2006102687A1 (fr)	2005-03-22	2006-09-28	The Trustees Of Columbia University In The City Of New York	Micro-agencement a base de liposomes et leurs methodes d'utilisation
PE20070717A1 (es) *	2005-11-08	2007-08-17	Millennium Pharm Inc	Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
MX336958B (es)	2005-11-15	2016-02-05	Philadelphia Children Hospital	Metodos y composiciones para modular la hemostasia.
US20070111322A1 (en)	2005-11-15	2007-05-17	Lin-Cheng Yang	Novel method of using inject printing for creating microarrays
EP1820508A1 (fr) *	2006-02-21	2007-08-22	CSL Behring GmbH	Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées
ES2849426T3 (es) *	2007-09-28	2021-08-18	Alexion Pharma Inc	Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
US8455439B2 (en) *	2008-11-14	2013-06-04	Portola Pharmaceuticals, Inc.	Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
CN104262479A (zh)	2008-12-19	2015-01-07	国家健康与医学研究院	丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
EP3604510A1 (fr) *	2009-03-30	2020-02-05	Portola Pharmaceuticals, Inc.	Antidotes pour inhibiteurs du facteur xa et procédés d'utilisation associes
CA2767858C (fr) *	2009-07-15	2019-02-12	Portola Pharmaceuticals, Inc.	Formulation de dose unique d'antidotes pour des inhibiteurs de facteur xa et procedes d'utilisation de celle-ci

2008
- 2008-09-26 ES ES14197779T patent/ES2849426T3/es active Active
- 2008-09-26 PL PL14197779T patent/PL2915564T3/pl unknown
- 2008-09-26 WO PCT/US2008/078014 patent/WO2009042962A2/fr active Application Filing
- 2008-09-26 JP JP2010527220A patent/JP5637561B2/ja active Active
- 2008-09-26 CN CN201310301566.3A patent/CN103446579B/zh active Active
- 2008-09-26 PL PL16167534T patent/PL3078743T3/pl unknown
- 2008-09-26 CN CN2008801079738A patent/CN101802188B/zh active Active
- 2008-09-26 PL PL08834136T patent/PL2193196T3/pl unknown
- 2008-09-26 CN CN201110447251.0A patent/CN102559644B/zh active Active
- 2008-09-26 HU HUE14197779A patent/HUE052423T2/hu unknown
- 2008-09-26 PT PT141977793T patent/PT2915564T/pt unknown
- 2008-09-26 DK DK16167534.3T patent/DK3078743T3/da active
- 2008-09-26 AU AU2008304192A patent/AU2008304192B9/en active Active
- 2008-09-26 ES ES08834136.7T patent/ES2597436T3/es active Active
- 2008-09-26 CN CN2011104472050A patent/CN102533702A/zh active Pending
- 2008-09-26 HU HUE16167534A patent/HUE050063T2/hu unknown
- 2008-09-26 DK DK08834136.7T patent/DK2193196T3/en active
- 2008-09-26 EP EP20198287.3A patent/EP3824902A1/fr active Pending
- 2008-09-26 PT PT88341367T patent/PT2193196T/pt unknown
- 2008-09-26 ES ES16167534T patent/ES2796623T3/es active Active
- 2008-09-26 KR KR1020177023761A patent/KR20170100071A/ko not_active Application Discontinuation
- 2008-09-26 BR BRPI0816837-7A patent/BRPI0816837B1/pt active IP Right Grant
- 2008-09-26 LT LTEP16167534.3T patent/LT3078743T/lt unknown
- 2008-09-26 MX MX2010003095A patent/MX2010003095A/es active IP Right Grant
- 2008-09-26 SI SI200832130T patent/SI3078743T1/sl unknown
- 2008-09-26 KR KR1020207001549A patent/KR102271404B1/ko active IP Right Grant
- 2008-09-26 HU HUE08834136A patent/HUE031647T2/en unknown
- 2008-09-26 PT PT161675343T patent/PT3078743T/pt unknown
- 2008-09-26 EP EP14197779.3A patent/EP2915564B1/fr active Active
- 2008-09-26 KR KR1020167003860A patent/KR102069498B1/ko active IP Right Grant
- 2008-09-26 KR KR1020107008718A patent/KR101698214B1/ko active IP Right Grant
- 2008-09-26 DK DK14197779.3T patent/DK2915564T3/da active
- 2008-09-26 SG SG2012072716A patent/SG185263A1/en unknown
- 2008-09-26 SI SI200831678A patent/SI2193196T1/sl unknown
- 2008-09-26 SI SI200832153T patent/SI2915564T1/sl unknown
- 2008-09-26 EP EP16167534.3A patent/EP3078743B1/fr active Active
- 2008-09-26 CA CA2697583A patent/CA2697583C/fr active Active
- 2008-09-26 US US12/239,651 patent/US8153590B2/en active Active
- 2008-09-26 EP EP08834136.7A patent/EP2193196B1/fr active Active
- 2008-09-26 LT LTEP08834136.7T patent/LT2193196T/lt unknown
- 2008-09-26 BR BR122022001846-7A patent/BR122022001846B1/pt active IP Right Grant
- 2008-09-26 NZ NZ583944A patent/NZ583944A/en unknown
2010
- 2010-02-16 IL IL203993A patent/IL203993A/en active IP Right Grant
- 2010-03-23 ZA ZA2010/02039A patent/ZA201002039B/en unknown
2012
- 2012-03-07 US US13/414,499 patent/US8455441B2/en active Active
2013
- 2013-04-11 AU AU2013205326A patent/AU2013205326A1/en not_active Abandoned
- 2013-05-07 US US13/889,014 patent/US9062298B2/en active Active
- 2013-06-11 US US13/915,525 patent/US8889129B2/en active Active
2014
- 2014-07-21 US US14/337,074 patent/US9388401B2/en active Active
- 2014-08-07 AU AU2014210620A patent/AU2014210620B2/en active Active
- 2014-08-19 JP JP2014166333A patent/JP6047127B2/ja active Active
- 2014-09-04 ZA ZA2014/06514A patent/ZA201406514B/en unknown
2015
- 2015-11-13 HK HK15111214.0A patent/HK1210443A1/xx unknown
2016
- 2016-06-08 US US15/176,461 patent/US10675335B2/en active Active
- 2016-10-03 HR HRP20161255TT patent/HRP20161255T1/hr unknown
- 2016-10-12 CY CY20161101020T patent/CY1118482T1/el unknown
- 2016-11-18 JP JP2016225290A patent/JP6300885B2/ja active Active
2017
- 2017-01-12 AU AU2017200212A patent/AU2017200212A1/en not_active Abandoned
- 2017-11-02 IL IL255397A patent/IL255397B/en active IP Right Grant
2018
- 2018-02-27 JP JP2018033229A patent/JP2018100290A/ja active Pending
2019
- 2019-02-18 IL IL264886A patent/IL264886B/en active IP Right Grant
- 2019-06-13 AU AU2019204123A patent/AU2019204123A1/en not_active Abandoned
- 2019-11-08 NO NO2019040C patent/NO2019040I1/no unknown
2020
- 2020-02-26 IL IL272926A patent/IL272926A/en unknown
- 2020-03-12 JP JP2020042919A patent/JP2020109113A/ja active Pending
- 2020-05-07 US US16/869,117 patent/US11839646B2/en active Active
- 2020-07-08 HR HRP20201071TT patent/HRP20201071T1/hr unknown
- 2020-08-04 CY CY20201100715T patent/CY1123504T1/el unknown
- 2020-09-09 NL NL301063C patent/NL301063I2/nl unknown
- 2020-09-23 NO NO2020033C patent/NO2020033I1/no unknown
- 2020-09-23 FR FR20C1045C patent/FR20C1045I2/fr active Active
- 2020-12-22 HU HUS2000057C patent/HUS2000057I1/hu unknown
- 2020-12-22 LT LTPA2020540C patent/LTC3078743I2/lt unknown
2021
- 2021-08-17 AU AU2021218033A patent/AU2021218033A1/en active Pending
2022
- 2022-07-29 JP JP2022121451A patent/JP2022153574A/ja active Pending
2023
- 2023-11-02 US US18/500,675 patent/US20240082367A1/en active Pending

Also Published As

Publication number	Publication date
CA2697583A1 (fr)	2009-04-02
BRPI0816837B1 (pt)	2022-10-18
KR20170100071A (ko)	2017-09-01
HRP20161255T1 (hr)	2016-12-02
CN103446579B (zh)	2015-04-22
CN101802188B (zh)	2013-08-21
US20140044773A1 (en)	2014-02-13
EP2193196B1 (fr)	2016-07-13
US8455441B2 (en)	2013-06-04
HUS2000057I1 (hu)	2021-01-28
AU2008304192A1 (en)	2009-04-02
AU2013205326A1 (en)	2013-05-09
SI2915564T1 (sl)	2021-03-31
LTPA2020540I1 (lt)	2021-01-11
HUE052423T2 (hu)	2021-04-28
US20120269788A1 (en)	2012-10-25
EP3078743B1 (fr)	2020-06-24
IL255397A0 (en)	2017-12-31
CN103446579A (zh)	2013-12-18
LT2193196T (lt)	2016-12-12
US9062298B2 (en)	2015-06-23
DK3078743T3 (da)	2020-08-10
ZA201406514B (en)	2016-10-26
PL2915564T3 (pl)	2021-07-19
AU2014210620B2 (en)	2016-05-12
BRPI0816837A2 (pt)	2020-08-18
IL255397B (en)	2019-03-31
LTC3078743I2 (lt)	2022-06-10
IL203993A (en)	2017-11-30
NZ583944A (en)	2012-06-29
AU2008304192B9 (en)	2024-02-01
EP2915564B1 (fr)	2020-11-04
LT3078743T (lt)	2020-09-25
SI2193196T1 (sl)	2017-01-31
KR20160025038A (ko)	2016-03-07
CY1123504T1 (el)	2021-06-25
MX2010003095A (es)	2010-04-09
NL301063I2 (nl)	2021-06-23
AU2008304192B2 (en)	2014-05-15
CA2697583C (fr)	2016-04-12
DK2193196T3 (en)	2016-11-07
WO2009042962A9 (fr)	2009-09-11
AU2014210620A1 (en)	2014-08-28
JP6300885B2 (ja)	2018-03-28
PT2915564T (pt)	2021-02-09
CY1118482T1 (el)	2017-07-12
NO2020033I1 (no)	2020-09-23
IL272926A (en)	2020-04-30
PL3078743T3 (pl)	2020-11-02
IL203993A0 (en)	2011-07-31
ES2849426T3 (es)	2021-08-18
KR20200009131A (ko)	2020-01-29
HRP20201071T1 (hr)	2020-10-30
FR20C1045I2 (fr)	2021-08-27
US20140079684A1 (en)	2014-03-20
JP6047127B2 (ja)	2016-12-21
AU2021218033A1 (en)	2021-09-09
US20090098119A1 (en)	2009-04-16
AU2013205326A8 (en)	2013-06-06
KR102069498B1 (ko)	2020-01-23
US20160354449A1 (en)	2016-12-08
HUE031647T2 (en)	2017-07-28
CN102533702A (zh)	2012-07-04
CN102559644A (zh)	2012-07-11
JP2020109113A (ja)	2020-07-16
ES2796623T3 (es)	2020-11-27
BR122022001846B1 (pt)	2022-12-27
US20240082367A1 (en)	2024-03-14
WO2009042962A2 (fr)	2009-04-02
PL2193196T3 (pl)	2017-07-31
EP3078743A1 (fr)	2016-10-12
JP2010539945A (ja)	2010-12-24
KR20100077172A (ko)	2010-07-07
US8889129B2 (en)	2014-11-18
EP3824902A1 (fr)	2021-05-26
SG185263A1 (en)	2012-11-29
EP2915564A1 (fr)	2015-09-09
JP2014218521A (ja)	2014-11-20
KR101698214B1 (ko)	2017-01-20
KR102271404B1 (ko)	2021-07-02
AU2019204123A1 (en)	2019-07-04
AU2008304192A2 (en)	2010-04-08
SI3078743T1 (sl)	2020-08-31
ES2597436T3 (es)	2017-01-18
JP2017043632A (ja)	2017-03-02
EP2193196A2 (fr)	2010-06-09
PT3078743T (pt)	2020-07-15
NO2019040I1 (no)	2019-11-08
IL264886B (en)	2020-03-31
DK2915564T3 (da)	2021-02-08
US10675335B2 (en)	2020-06-09
US20150057228A1 (en)	2015-02-26
JP2018100290A (ja)	2018-06-28
WO2009042962A3 (fr)	2009-06-04
CN102559644B (zh)	2015-03-25
US20200276280A1 (en)	2020-09-03
ZA201002039B (en)	2015-11-25
AU2017200212A1 (en)	2017-02-02
HK1210443A1 (en)	2016-04-22
JP2022153574A (ja)	2022-10-12
PT2193196T (pt)	2016-10-24
US9388401B2 (en)	2016-07-12
CN101802188A (zh)	2010-08-11
JP5637561B2 (ja)	2014-12-10
US8153590B2 (en)	2012-04-10
US11839646B2 (en)	2023-12-12
NL301063I1 (fr)	2020-09-16
HUE050063T2 (hu)	2020-11-30

Publication	Publication Date	Title
FR20C1045I1 (fr)	2020-10-30
CN300838043S (zh)	2008-10-15	包(7d21216)
CN300729751S (zh)	2008-01-09	工艺品(金尊)
CN300729616S (zh)	2008-01-09	瓶盖(q28-410)
CN300729596S (zh)	2008-01-09	食品包装袋(a)
CN300729506S (zh)	2008-01-09	包装盒(素图)
CN300729466S (zh)	2008-01-09	包装盒(单门2)
CN300728994S (zh)	2008-01-09	床头(3)
CN300728900S (zh)	2008-01-09	睡床(84)
CN300728765S (zh)	2008-01-09	墙纸(15)
CN300728503S (zh)	2008-01-02	搅肉机(机灵兔)
CN300728345S (zh)	2008-01-02	金属探测自控门(2007b)
CN300728163S (zh)	2008-01-02	***(振忠)
CN300728120S (zh)	2008-01-02	健身板(神奇一)
CN300728005S (zh)	2008-01-02	电梯用指示器
CN300727977S (zh)	2008-01-02	学习卡片(英语拼音方案)
CN300727858S (zh)	2008-01-02	圆珠笔(社军1)
CN300727613S (zh)	2008-01-02	鼓风式微型散热模组(联合一)
CN300727420S (zh)	2008-01-02	驾驶室侧位内饰
CN300727410S (zh)	2008-01-02	汽车用后门
CN300727406S (zh)	2008-01-02	汽车用前保险杠
CN300727397S (zh)	2008-01-02	汽车前保险杠
CN300727183S (zh)	2008-01-02	包装袋(谷满多生物有机肥)
CN300727170S (zh)	2008-01-02	洗衣粉包装袋(花洁浪)
CN300726843S (zh)	2008-01-02	包装罐(曲线型)